These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29929486)

  • 1. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
    BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
    Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
    Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases.
    Peltonen R; Hagström J; Tervahartiala T; Sorsa T; Haglund C; Isoniemi H
    Oncology; 2021; 99(3):144-160. PubMed ID: 33027796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
    Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
    Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality.
    Hästbacka J; Linko R; Tervahartiala T; Varpula T; Hovilehto S; Parviainen I; Vaara ST; Sorsa T; Pettilä V
    Anesth Analg; 2014 Apr; 118(4):790-8. PubMed ID: 24651234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
    Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
    Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer.
    Carpén T; Sorsa T; Jouhi L; Tervahartiala T; Haglund C; Syrjänen S; Tarkkanen J; Mohamed H; Mäkitie A; Hagström J; Mattila PS
    Cancer Immunol Immunother; 2019 Aug; 68(8):1263-1272. PubMed ID: 31240326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
    Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
    Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to predict the relapse after surgery or radiofrequency of liver metastases of colorectal cancer? Interest of the serum kinetic variation of a matrix metalloproteinase cluster].
    Frenoux C; Rebischung C; Quesada JL; Mendosa C; Letoublon C; Trocmé C
    Bull Cancer; 2018 Oct; 105(10):884-895. PubMed ID: 30243479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Matrix Metalloproteinase-8 and Myeloperoxidase Predict Survival after Resection of Colorectal Liver Metastases.
    Reijonen P; Peltonen R; Tervahartiala T; Sorsa T; Isoniemi H
    Oncology; 2021; 99(12):766-779. PubMed ID: 34571507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
    Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
    Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
    Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
    Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
    Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
    Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.